根据名称进行药物检索

Serzone 与 Tacrolimus Injection

Serzone 与 Tacrolimus Injection互相作用以及同时服用的可能性。

检测结果:

Serzone <> Tacrolimus Injection

现实性: 18.12.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用藤一起奈法唑酮可能增加的影响藤并导致对肾脏的损害或引起神经损失。告诉你的医生，如果你遇到头晕，麻木、皮肤刺痛、肌肉颤搐，或癫痫发作可能的迹象神经损伤。跟你的医生，如果你开发的热、冷、身体疼痛，流感的症状，并严重疼痛，在你的上部胃扩展到你回来。如果你采取这两种药物在一起，告诉医生，如果你有任何的这些症状。你可能需要的剂量调整或特别的测试如果使用这两种药物。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

密切监测:共同给予有效抑制剂的CYP450 3A4可能会显着增加的血液浓度的克莫司，其主要代谢的同工酶在肠和肝脏。已经有许多报告和药物动力学研究医学文献中的藤的互动与各种有效的CYP450 3A4抑制剂，包括唑抗真菌剂、大环内酯类抗生素和蛋白酶抑制剂。肾毒性和其他不良影响(例如高血钾、高血糖、溶血性贫血、血尿毒症、神经毒性)在协会有显着提高服用此药物的血液水平已经报道，因此有必要大幅削减或中断藤给药。

管理：谨慎建议时藤是用有效的CYP450 3A4抑制剂。剂量的减少和/或延长的配量时间间隔藤将可能是需要的。频繁的监测藤整个血液水平应当执行期间和之后停止CYP450 3A4抑制剂，与藤剂量进行相应的调整。此外，患者应密切监测对发展的严重不良影响，如肾中毒、淋巴瘤和其他恶性肿瘤、传染病、糖尿病、神经毒性(震颤、感觉异常,脑病，谵妄、昏迷),高血钾,脱延长，心肌肥大和高血压。患者应建议寻求迅速的医疗注意，如果他们遇到的症状可能表明发生心动de扭转性，例如头晕、头晕、昏厥，心悸，不规则的心律、呼吸急促，或者昏厥。

来源

Venkatakrishnan K, von Moltke LL, Greenblatt DJ "Effects of the antifungal agents on oxidative drug metabolism: clinical relevance." Clin Pharmacokinet 38 (2000): 111-80
Schonder KS, Shullo MA, Okusanya O "Tacrolimus and lopinavir/ritonavir interaction in liver transplantation." Ann Pharmacother 37 (2003): 1793-6
Jain AB, Venkataramanan R, Eghtesad B, et al. "Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients." Liver Transpl 9 (2003): 954-60
Assan R, Fredj G, Larger E, Feutren G, Bismuth H "FK 506/fluconazole interaction enhances FK 506 nephrotoxicity." Diabete Metab 20 (1994): 49-52
Cerner Multum, Inc. "Australian Product Information." O 0
Capone D, Gentile A, Imperatore P, Palmiero G, Basile V "Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient." Ann Pharmacother 33 (1999): 1124-5
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Jain AK, Venkataramanan R, Shapiro R, et al. "The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients." Liver Transpl 8 (2002): 841-5
Billaud EM, Guillemain R, Tacco F, Chevalier P "Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients." Br J Clin Pharmacol 46 (1998): 271-4
Homma S, Takahashi KI, Nihei S, Kato F, Sugihara S, Nunoda S "The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients." Int Heart J (2014):
Gomez G, Alvarez ML, Errasti P, Lavilla FJ, Garcia N, Ballester B, Garcia I, Purroy A "Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin." Transplant Proc 31 (1999): 2250-1
"Product Information. Prograf (tacrolimus)." Fujisawa, Deerfield, IL.
Kunicki PK, Sobieszczanska-Malek M "Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient." Ther Drug Monit 27 (2005): 107-108
Floren LC, Bekersky I, Benet LZ, et al. "Tacrolimus oral bioavailability doubles with coadministration of ketoconazole." Clin Pharmacol Ther 62 (1997): 41-9
Shaeffer MS, Collier D, Sorrell MF "Interaction between FK506 and erythromycin." Ann Pharmacother 28 (1994): 280-1
Jain AK, Venkataramanan R, Shapiro R, et al. "Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients." Transplant Proc 34 (2002): 1540-1
Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16
Pai MP, Allen S "Voriconazole inhibition of tacrolimus metabolism." Clin Infect Dis 36 (2003): 1089-91
Venkataramanan R, Zang S, Gayowski T, Singh N "Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes." Antimicrob Agents Chemother 46 (2002): 3091-3
Albengres E, Le Louet H, Tillement JP "Systemic antifungal agents. Drug interactions of clinical significance." Drug Saf 18 (1998): 83-97
Barau C, Blouin P, Creput C, Taburet AM, Durrbach A, Furlan V "Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient." Fundam Clin Pharmacol 23 (2009): 423-5
Pea F, Furlanut M "Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions." Clin Pharmacokinet 40 (2001): 833-868
Pea F, Tavio M, Pavan F, et al. "Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients." Antivir Ther 13 (2008): 739-42
Wolter K, Wagner K, Philipp T, Fritschka E "Interaction between FK 506 and clarithromycin in a renal transplant patient." Eur J Clin Pharmacol 47 (1994): 207-8
Moreno M, Latorre A, Manzanares C, et al "Clinical management of tacrolimus drug interactions in renal transplant patients." Transplant Proc 31 (1999): 2252-3
Furlan V, Perello L, Jacquemin E, Debray D, Taburet AM "Interactions between FK506 and rifampin or erythromycin in pediatric liver recipients." Transplantation 59 (1995): 1217-8
Soltero L, Carbajal H, Rodriguez-Montalvo C, Valdes A "Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects." Transplant Proc 35 (2003): 1319-21
Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE "Interaction between FK506 and clotrimazole in a liver transplant recipient." Transplantation 52 (1991): 1086-7
Manez R, Martin M, Raman V, et al. "Fluconazole therapy in transplant recipients receiving FK506." Transplantation 57 (1994): 1521-3
Tsapepas DS, Webber AB, Aull MJ, Figueiro JM, Saal SD "Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient." Am J Health Syst Pharm 68 (2011): 138-42
Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR "Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients." Transplantation 61 (1996): 1268-72
Parissis H, Gould K, Dark J "Dangerous drug interactions leading to hemolytic uremic syndrome following lung transplantation." J Cardiothorac Surg 5 (2010): 70
Macias MO, Salvador P, Hurtado JL, Martin I "Tacrolimus-itraconazole interaction in a kidney transplant patient." Ann Pharmacother 34 (2000): 536
Mertz D, Battegay M, Marzolini C, Mayr M "Drug-Drug Interaction in a Kidney Transplant Recipient Receiving HIV Salvage Therapy and Tacrolimus." Am J Kidney Dis (2009):
Ibrahim RB, Abella EM, Chandrasekar PH "Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation." Ann Pharmacother 36 (2002): 1971-1972
Olyaei AJ, deMattos AM, Norman DJ, Bennett WM "Interaction between tacrolimus and nefazodone in a stable renal transplant recipient." Pharmacotherapy 18 (1998): 1356-9
Jensen C, Jordan M, Shapiro R, et al. "Interaction between tacrolimus and erythromycin." Lancet 344 (1994): 825
Teicher E, Vincent I, Bonhomme-Faivre L, et al. "Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study." Clin Pharmacokinet 46 (2007): 941-52
Katari SR, Magnone M, Shapiro R, et al "Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients." Clin Transplant 11 (1997): 237-42
Vasquez EM, Pollak R, Benedetti E "Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients." Clin Transplant 15 (2001): 95-9
Dodds-Ashley E "Management of drug and food interactions with azole antifungal agents in transplant recipients." Pharmacotherapy 30 (2010): 842-54